FDA Panel Recommends Against Genasense Approval in CLL
Antisense drug developer Genta said this week that the US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recommended against the agency’s approval of Genasense for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
